These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37945694)

  • 1. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.
    Heresco-Levy U; Lerer B
    Mol Psychiatry; 2024 Jan; 29(1):146-152. PubMed ID: 37945694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.
    Forsyth JK; Bachman P; Mathalon DH; Roach BJ; Ye E; Asarnow RF
    Schizophr Bull; 2017 Sep; 43(5):1123-1133. PubMed ID: 28338977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-Cycloserine enhances the bidirectional range of NMDAR-dependent hippocampal synaptic plasticity.
    Vestring S; Dorner A; Scholliers J; Ehrenberger K; Kiss A; Arenz L; Theiss A; Rossner P; Frase S; Du Vinage C; Wendler E; Serchov T; Domschke K; Bischofberger J; Normann C
    Transl Psychiatry; 2024 Jan; 14(1):18. PubMed ID: 38195548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings.
    Levin R; Dor-Abarbanel AE; Edelman S; Durrant AR; Hashimoto K; Javitt DC; Heresco-Levy U
    J Psychiatr Res; 2015 Feb; 61():188-95. PubMed ID: 25554623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.
    Inserra A; De Gregorio D; Gobbi G
    Pharmacol Rev; 2021 Jan; 73(1):202-277. PubMed ID: 33328244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-Cycloserine Restores Experience-Dependent Neuroplasticity after Traumatic Brain Injury in the Developing Rat Brain.
    Sta Maria NS; Reger ML; Cai Y; Baquing MAT; Buen F; Ponnaluri A; Hovda DA; Harris NG; Giza CC
    J Neurotrauma; 2017 Apr; 34(8):1692-1702. PubMed ID: 27931146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity.
    Ingram R; Kang H; Lightman S; Jane DE; Bortolotto ZA; Collingridge GL; Lodge D; Volianskis A
    Neuropharmacology; 2018 Nov; 142():30-40. PubMed ID: 29885421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurotrophic mechanisms of psychedelic therapy].
    Corne R; Mongeau R
    Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Amino Acid d-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms.
    Wei IH; Chen KT; Tsai MH; Wu CH; Lane HY; Huang CC
    J Agric Food Chem; 2017 Dec; 65(49):10792-10803. PubMed ID: 29161812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.
    Olson DE
    Biochemistry; 2022 Feb; 61(3):127-136. PubMed ID: 35060714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices.
    Rouaud E; Billard JM
    Br J Pharmacol; 2003 Nov; 140(6):1051-6. PubMed ID: 14530208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The possible place for psychedelics in pharmacotherapy of mental disorders.
    Wojtas A
    Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulatory effects of an NMDAR partial agonist in MK-801-induced memory impairment.
    Vishnoi S; Raisuddin S; Parvez S
    Neuroscience; 2015 Dec; 311():22-33. PubMed ID: 26454025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.
    Savalia NK; Shao LX; Kwan AC
    Trends Neurosci; 2021 Apr; 44(4):260-275. PubMed ID: 33358035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
    Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
    Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approach to the role of NMDA receptors in traumatic brain injury.
    Shohami E; Biegon A
    CNS Neurol Disord Drug Targets; 2014; 13(4):567-73. PubMed ID: 24168367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats.
    Davis-Reyes BD; Smith AE; Xu J; Cunningham KA; Zhou J; Anastasio NC
    Behav Pharmacol; 2021 Jun; 32(4):335-344. PubMed ID: 33595955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.
    Aleksandrova LR; Phillips AG
    Trends Pharmacol Sci; 2021 Nov; 42(11):929-942. PubMed ID: 34565579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by D-cycloserine.
    Billard JM; Rouaud E
    Eur J Neurosci; 2007 Apr; 25(8):2260-8. PubMed ID: 17445224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.